公开(公告)号：EP1121936A4

公开(公告)日：2004-11-17

申请号：EP99943391

申请日：1999-09-17

申请人： DAIICHI SEIYAKU CO

发明人： GOTO MASAAKI ,  TOMOYASU AKIHIRO ,  YAMAGUCHI KYOJI ,  KINOSAKI MASAHIKO ,  NAKAGAWA NOBUAKI

IPC分类号： A61K38/22 ,  A61K38/17 ,  A61P3/04

CPC分类号： A61K38/22 ,  Y10S514/909

摘要： Novel preventives and/or remedies for obesity. These preventives and/or remedies contain as the active ingredient stanniocalcin. Because of having an excellent activity of inhibiting the differentiation and maturation of adipocytes, they are useful as drugs for preventing and/or treating obesity.

公开(公告)号：EP0925791A4

公开(公告)日：2004-06-16

申请号：EP98909799

申请日：1998-03-20

申请人： DAIICHI SEIYAKU CO

发明人： KINOSAKI MASAHIKO ,  OGAWA HIROMI ,  MASUNAGA HIROAKI ,  KOBAYASHI FUMIE ,  YAMAGUCHI KYOJI ,  HIGASHIO KANJI

IPC分类号： A61K38/00 ,  A61K38/22 ,  A61P13/02 ,  A61P13/12 ,  A61P15/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/52 ,  A61K38/18

CPC分类号： C07K14/4753 ,  A61K38/00 ,  C07K14/52

摘要： A preventive and/or therapeutic agent for kidney diseases, containing as the active ingredient a tumor cytotoxic factor II (TCF-II) mutant which has undergone point mutation. The mutant is TCF-II wherein the Arg-Lys-Arg-Arg amino acid sequence beginning at the second position from the N-terminal is replaced by Ala-Ala-Ala-Ala or the Lys-Ile-Lys-Thr-Lys-Lys amino acid sequence beginning at the 27th position therefrom is replaced by Ala-Ile-Ala-Thr-Ala-Ala.

公开(公告)号：EP1070758A4

公开(公告)日：2005-01-12

申请号：EP99913613

申请日：1999-04-09

申请人： DAIICHI SEIYAKU CO

发明人： GOTO MASAAKI ,  TOMOYASU AKIHIRO ,  YANO KAZUKI ,  KOBAYASHI FUMIE ,  NAKAGAWA NOBUAKI ,  YASUDA HISATAKA ,  YAMAGUCHI KYOJI ,  KINOSAKI MASAHIKO ,  MOCHIZUKI SHIN-ICHI ,  NAKAKARUMAI TADASHI ,  MORINAGA TOMONORI ,  TSUDA EISUKE ,  HIGASHIO KANJI

IPC分类号： A61K38/00 ,  C07K14/47 ,  C12N15/12 ,  C07K1/16 ,  C07K1/20 ,  C07K1/22 ,  C12N11/14 ,  C12P21/02 ,  C12R1/91

CPC分类号： C07K14/47 ,  A61K38/00

摘要： A novel protein which is a glycoprotein having activities of suppressing the differentiation and/or maturation of adipocytes, having a molecular weight of about 45 kDa under nonreducing conditions and about 28 kDa and/or about 23 kDa under reducing conditions, and having an affinity for heparin. A process for producing the above protein which comprises culturing human fibroblasts and purifying the product from the liquid culture medium by ion exchange column, affinity column and reversed phase column chromatographs. A cDNA encoding the above protein and a process for producing the above protein by using this cDNA. This protein is useful in medicinal compositions aiming at preventing and/or treating obesity, as an antigen for establishing immunological diagnosis, etc.